Advertisement
Advertisement
PROK
ProKidney Corp. Class A Ordinary Shares
1.64
USDSponsored
0.00
0.00%
Aug 07, 15:58 UTC -4
Closed
After-Market
1.66
+0.02
+0.98%
PROK Earnings Reports
Positive Surprise Ratio
PROK beat 12 of 15 last estimates.
80%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
ProKidney Corp. Class A Ordinary Shares earnings per share and revenue
On May 15, 2026, PROK reported earnings of -0.14 USD per share (EPS) for Q1 26, beating the estimate of -0.14 USD, resulting in a 0.57% surprise. Revenue reached 226.00 thousand, compared to an expected 146.54 thousand, with a 54.22% difference. The market reacted with a -2.92% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
electroCore, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.33
Surprise
+23.40%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
FAQ
What were ProKidney Corp. Class A Ordinary Shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, ProKidney Corp. Class A Ordinary Shares reported EPS of -$0.14, beating estimates by 0.57%, and revenue of $226.00K, 54.22% above expectations.
How did the market react to ProKidney Corp. Class A Ordinary Shares's Q1 2026 earnings?
The stock price moved down -2.92%, changed from $1.71 before the earnings release to $1.66 the day after.
When is ProKidney Corp. Class A Ordinary Shares expected to report next?
The next earning report is scheduled for --.
What are the forecasts for ProKidney Corp. Class A Ordinary Shares's next earnings report?
Based on --
analysts, ProKidney Corp. Class A Ordinary Shares is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement